Strategic partnerships CURE operates as a vertically integrated drug delivery and development company with a patented delivery system (CureFilm) and cGMP manufacturing capabilities, suggesting strong collaboration potential with pharma and cannabis-focused partners seeking advanced dosage forms and reliable manufacturing.

Cannabis delivery niche With active partnerships across the U.S., Canada, Israel, and Germany in the pharmaceutical cannabis space, CURE offers a pathway for co-development, contract manufacturing, or licensing of cannabis-derived actives using its CureFilm platform to expand into new markets.

Mid-market focus Revenue in the range of 10–25 million and a lean team (11–50 employees) indicate agility and cost-efficient collaboration opportunities for mid-market pharma companies seeking scalable, high-tech delivery solutions without large enterprise engagement overhead.

Clinical development leverage Historical launches of CureFilm products and multiple clinical programs signal readiness for sponsored trials or joint development agreements, presenting opportunities to partner on phase-focused studies or pipeline expansions in specialized delivery platforms.

Innovation-driven value CURE emphasizes patient experience and safety through advanced dosage forms, offering sales angles around differentiating products, improved bioavailability, and potential FDA/regulatory appeal for partner products seeking differentiated, manufacturable formulations.